Patent Application
App. No. 16/561,525
METHODS FOR TREATING INFECTION
Loading inventors, assignments & file history…
Abstract
The present invention provides new methods and kits for treating and preventing bacterial infection.
Claims (4)
1 - 31 . (canceled)
32 . A method of treating rifampin resistant C. difficile infection (CDI) in a subject comprising administering from 25 mg to 3000 mg per day of rifaximin to the subject, wherein the CDI is caused by a hypervirulant strain of C. difficile comprising genes encoding Toxin A, Toxin B, and Binary Toxin, and further comprising a deletion in the tdcC gene.
33 . The method of claim 1 , wherein the rifaximin is administered twice daily to the subject.
34 . The method of claim 1 , wherein the rifaximin is administered three times daily to the subject.
Assignments (6)
RELEASE OF SECURITY INTEREST
Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT
Recorded Feb 4, 2020
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH & LOMB INCORPORATED; DOW PHARMACEUTICAL SCIENCES, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; BAUSCH HEALTH US, LLC; SANTARUS, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 051797/0416 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT
Recorded Feb 4, 2020
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH & LOMB INCORPORATED; DOW PHARMACEUTICAL SCIENCES, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; BAUSCH HEALTH US, LLC; SANTARUS, INC.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT FOR THE NOTEHOLDER SECURED PARTIES
Reel/Frame 051797/0491 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 21, 2020
From: GOLDEN, PAM
To: SALIX PHARMACEUTICALS, LTD
Reel/Frame 051567/0797 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 21, 2020
From: SALIX PHARMACEUTICALS, LTD
To: SALIX PHARMACEUTICALS, INC.
Reel/Frame 051567/0861 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 21, 2020
From: DU PONT, HERBERT L.; JIANG, ZHI-DONG; BROWN, ERIC; DARKOH, CHARLES
To: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 051567/0941 →